Credit Suisse Ag I Teos Therapeutics, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 26,661 shares of ITOS stock, worth $199,157. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,661

Previous 26,661 -0.0%

Holding current value

$199,157

Previous $291,000 24.74%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$8.57 - $11.06 $66,468 - $85,781	7,756 Added 41.03%	26,661 $291,000
Q3 2023 Nov 13, 2023	SELL	$10.95 - $14.6 $49,406 - $65,875	-4,512 Reduced 19.27%	18,905 $207,000
Q2 2023 Aug 11, 2023	BUY	$12.93 - $18.05 $7,150 - $9,981	553 Added 2.42%	23,417 $310,000
Q1 2023 May 10, 2023	BUY	$13.02 - $22.62 $20,936 - $36,372	1,608 Added 7.56%	22,864 $311,000
Q4 2022 Feb 13, 2023	SELL	$17.77 - $21.6 $9,578 - $11,642	-539 Reduced 2.47%	21,256 $415,000
Q3 2022 Nov 10, 2022	BUY	$18.6 - $27.25 $234,453 - $343,486	12,605 Added 137.16%	21,795 $415,000
Q2 2022 Aug 12, 2022	SELL	$16.57 - $35.1 $18,508 - $39,206	-1,117 Reduced 10.84%	9,190 $189,000
Q1 2022 May 16, 2022	SELL	$31.92 - $47.45 $38,144 - $56,702	-1,195 Reduced 10.39%	10,307 $331,000
Q4 2021 Feb 14, 2022	BUY	$26.23 - $47.86 $301,697 - $550,485	11,502 New	11,502 $535,000
Q2 2021 Aug 16, 2021	SELL	$17.9 - $36.1 $159,524 - $321,723	-8,912 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$30.86 - $44.2 $758,662 - $1.09 Million	-24,584 Reduced 73.39%	8,912 $304,000
Q4 2020 Feb 12, 2021	BUY	$21.59 - $33.95 $723,178 - $1.14 Million	33,496 New	33,496 $1.13 Million

Others Institutions Holding ITOS

# of Institutions

166

Shares Held

36.6M

Call Options Held

1.95M

Put Options Held

374K

View Full List

About iTeos Therapeutics, Inc.

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $266M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

More about ITOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account